Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | RP2 |
| Trade Name | |
| Synonyms | RP-2|RP 2 |
| Drug Descriptions |
RP2 is an oncolytic virus engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF) and an antibody-like molecule targeted against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which may lead to activation of anti-tumor immune response and tumor cell killing (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C176748 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Bevacizumab + RP2 | Atezolizumab Bevacizumab RP2 | 0 | 1 |
| Docetaxel + Filgrastim + Fluorouracil + Leucovorin + Oxaliplatin + RP2 | Docetaxel Filgrastim Fluorouracil Leucovorin Oxaliplatin RP2 | 0 | 1 |
| Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin + Pegfilgrastim + RP2 | Docetaxel Fluorouracil Leucovorin Oxaliplatin Pegfilgrastim RP2 | 0 | 1 |
| Durvalumab + RP2 | Durvalumab RP2 | 0 | 1 |
| Nivolumab + RP2 | Nivolumab RP2 | 0 | 2 |
| RP2 | RP2 | 0 | 1 |
| RP2 + Tivozanib | RP2 Tivozanib | 0 | 1 |